Bifeprunox versus placebo for schizophrenia.

ABSTRACT:

Background

Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve the drug for acute or long-term symptoms of schizophrenia because more research was required to demonstrate convincing effects "beyond those already achieved" with currently licenced drugs. There were also concerns expressed over one death of a person whilst on the drug.

Objectives

To investigate the clinical and adverse effects of bifeprunox for people with schizophrenia.

Search methods

We searched the Cochrane Schizophrenia Group's Trials Register on 23 October 2015, which is based on regular searches of MEDLINE, EMBASE, C

SUBMITTER: Chattopadhyay A 

PROVIDER: S-EPMC6457956 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature